Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib
Background Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival. Methods Patients with metastatic...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2019-11, Vol.21 (11), p.1518-1523 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1523 |
|---|---|
| container_issue | 11 |
| container_start_page | 1518 |
| container_title | Clinical & translational oncology |
| container_volume | 21 |
| creator | Gökyer, A. Küçükarda, A. Köstek, O. Hacıoğlu, M. B. Sunal, B. S. Demircan, N. C. Uzunoğlu, S. Solak, S. İşsever, K. Çiçin, İ. Erdoğan, B. |
| description | Background
Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.
Methods
Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.
Results
Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (
p
= 0.005). Three patients suffered from grade 3–4 toxicity. Hand–foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7–31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5–35.7) (
p
= 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1–16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7–20.1) (
p
= 0.65).
Conclusion
Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia. |
| doi_str_mv | 10.1007/s12094-019-02080-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2191358285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2191358285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-9ca9cef54da1dff182a79aca66405c3e06989bdb1bd6c48bc4e286636697e56c3</originalsourceid><addsrcrecordid>eNp9kM1OHDEQhK0IFH6SF8gh8pHLEHvs8drHCEFAWikSAomb5enpWYxm7I3tZcMh746TXTjm1K3qqrL8EfKFs3PO2OJb5i0zsmHcNKxlmjXyAznmyphGsK472O9M6ocjcpLzE6uq4vwjORJMKy20PiZ_bnFyxcdAeyxbxECzSxDXGLyjLgx0iBmbyc---LCiJf724MsL9YGuaw5DyXTryyOdsbhcqgQU4hQTQnETBRcAE90-RloV9M841GUVkxvrC_0ncji6KePn_Twl91eXdxfXzfLnj5uL78sGhFyUxoAzgGMnB8eHceS6dQvjwCklWQcCmTLa9EPP-0GB1D1IbLVSQimzwE6BOCVnu951ir82mIudfQacJhcwbrJtueGi063uqrXdWSHFnBOOdp387NKL5cz-xW532G3Fbv9ht7KGvu77N_2Mw3vkjXM1iJ0h11NYYbJPcZNC_fP_al8BxMCRWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191358285</pqid></control><display><type>article</type><title>Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gökyer, A. ; Küçükarda, A. ; Köstek, O. ; Hacıoğlu, M. B. ; Sunal, B. S. ; Demircan, N. C. ; Uzunoğlu, S. ; Solak, S. ; İşsever, K. ; Çiçin, İ. ; Erdoğan, B.</creator><creatorcontrib>Gökyer, A. ; Küçükarda, A. ; Köstek, O. ; Hacıoğlu, M. B. ; Sunal, B. S. ; Demircan, N. C. ; Uzunoğlu, S. ; Solak, S. ; İşsever, K. ; Çiçin, İ. ; Erdoğan, B.</creatorcontrib><description>Background
Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.
Methods
Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.
Results
Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (
p
= 0.005). Three patients suffered from grade 3–4 toxicity. Hand–foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7–31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5–35.7) (
p
= 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1–16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7–20.1) (
p
= 0.65).
Conclusion
Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-019-02080-4</identifier><identifier>PMID: 30868388</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Disease Susceptibility ; Exanthema - chemically induced ; Female ; Hand-Foot Syndrome - etiology ; Humans ; Hypertension - chemically induced ; Kaplan-Meier Estimate ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mucous Membrane ; Oncology ; Phenylurea Compounds - administration & dosage ; Phenylurea Compounds - adverse effects ; Progression-Free Survival ; Pyridines - administration & dosage ; Pyridines - adverse effects ; Research Article ; Retrospective Studies ; Sarcopenia - chemically induced ; Sarcopenia - diagnostic imaging ; Sarcopenia - mortality ; Tomography, X-Ray Computed</subject><ispartof>Clinical & translational oncology, 2019-11, Vol.21 (11), p.1518-1523</ispartof><rights>Federación de Sociedades Españolas de Oncología (FESEO) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-9ca9cef54da1dff182a79aca66405c3e06989bdb1bd6c48bc4e286636697e56c3</citedby><cites>FETCH-LOGICAL-c347t-9ca9cef54da1dff182a79aca66405c3e06989bdb1bd6c48bc4e286636697e56c3</cites><orcidid>0000-0002-1653-6155</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-019-02080-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-019-02080-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30868388$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gökyer, A.</creatorcontrib><creatorcontrib>Küçükarda, A.</creatorcontrib><creatorcontrib>Köstek, O.</creatorcontrib><creatorcontrib>Hacıoğlu, M. B.</creatorcontrib><creatorcontrib>Sunal, B. S.</creatorcontrib><creatorcontrib>Demircan, N. C.</creatorcontrib><creatorcontrib>Uzunoğlu, S.</creatorcontrib><creatorcontrib>Solak, S.</creatorcontrib><creatorcontrib>İşsever, K.</creatorcontrib><creatorcontrib>Çiçin, İ.</creatorcontrib><creatorcontrib>Erdoğan, B.</creatorcontrib><title>Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Background
Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.
Methods
Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.
Results
Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (
p
= 0.005). Three patients suffered from grade 3–4 toxicity. Hand–foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7–31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5–35.7) (
p
= 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1–16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7–20.1) (
p
= 0.65).
Conclusion
Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.</description><subject>Aged</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Disease Susceptibility</subject><subject>Exanthema - chemically induced</subject><subject>Female</subject><subject>Hand-Foot Syndrome - etiology</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mucous Membrane</subject><subject>Oncology</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Progression-Free Survival</subject><subject>Pyridines - administration & dosage</subject><subject>Pyridines - adverse effects</subject><subject>Research Article</subject><subject>Retrospective Studies</subject><subject>Sarcopenia - chemically induced</subject><subject>Sarcopenia - diagnostic imaging</subject><subject>Sarcopenia - mortality</subject><subject>Tomography, X-Ray Computed</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OHDEQhK0IFH6SF8gh8pHLEHvs8drHCEFAWikSAomb5enpWYxm7I3tZcMh746TXTjm1K3qqrL8EfKFs3PO2OJb5i0zsmHcNKxlmjXyAznmyphGsK472O9M6ocjcpLzE6uq4vwjORJMKy20PiZ_bnFyxcdAeyxbxECzSxDXGLyjLgx0iBmbyc---LCiJf724MsL9YGuaw5DyXTryyOdsbhcqgQU4hQTQnETBRcAE90-RloV9M841GUVkxvrC_0ncji6KePn_Twl91eXdxfXzfLnj5uL78sGhFyUxoAzgGMnB8eHceS6dQvjwCklWQcCmTLa9EPP-0GB1D1IbLVSQimzwE6BOCVnu951ir82mIudfQacJhcwbrJtueGi063uqrXdWSHFnBOOdp387NKL5cz-xW532G3Fbv9ht7KGvu77N_2Mw3vkjXM1iJ0h11NYYbJPcZNC_fP_al8BxMCRWQ</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Gökyer, A.</creator><creator>Küçükarda, A.</creator><creator>Köstek, O.</creator><creator>Hacıoğlu, M. B.</creator><creator>Sunal, B. S.</creator><creator>Demircan, N. C.</creator><creator>Uzunoğlu, S.</creator><creator>Solak, S.</creator><creator>İşsever, K.</creator><creator>Çiçin, İ.</creator><creator>Erdoğan, B.</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1653-6155</orcidid></search><sort><creationdate>20191101</creationdate><title>Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib</title><author>Gökyer, A. ; Küçükarda, A. ; Köstek, O. ; Hacıoğlu, M. B. ; Sunal, B. S. ; Demircan, N. C. ; Uzunoğlu, S. ; Solak, S. ; İşsever, K. ; Çiçin, İ. ; Erdoğan, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-9ca9cef54da1dff182a79aca66405c3e06989bdb1bd6c48bc4e286636697e56c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Disease Susceptibility</topic><topic>Exanthema - chemically induced</topic><topic>Female</topic><topic>Hand-Foot Syndrome - etiology</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mucous Membrane</topic><topic>Oncology</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Progression-Free Survival</topic><topic>Pyridines - administration & dosage</topic><topic>Pyridines - adverse effects</topic><topic>Research Article</topic><topic>Retrospective Studies</topic><topic>Sarcopenia - chemically induced</topic><topic>Sarcopenia - diagnostic imaging</topic><topic>Sarcopenia - mortality</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gökyer, A.</creatorcontrib><creatorcontrib>Küçükarda, A.</creatorcontrib><creatorcontrib>Köstek, O.</creatorcontrib><creatorcontrib>Hacıoğlu, M. B.</creatorcontrib><creatorcontrib>Sunal, B. S.</creatorcontrib><creatorcontrib>Demircan, N. C.</creatorcontrib><creatorcontrib>Uzunoğlu, S.</creatorcontrib><creatorcontrib>Solak, S.</creatorcontrib><creatorcontrib>İşsever, K.</creatorcontrib><creatorcontrib>Çiçin, İ.</creatorcontrib><creatorcontrib>Erdoğan, B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gökyer, A.</au><au>Küçükarda, A.</au><au>Köstek, O.</au><au>Hacıoğlu, M. B.</au><au>Sunal, B. S.</au><au>Demircan, N. C.</au><au>Uzunoğlu, S.</au><au>Solak, S.</au><au>İşsever, K.</au><au>Çiçin, İ.</au><au>Erdoğan, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>21</volume><issue>11</issue><spage>1518</spage><epage>1523</epage><pages>1518-1523</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Background
Sarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.
Methods
Patients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.
Results
Thirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (
p
= 0.005). Three patients suffered from grade 3–4 toxicity. Hand–foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7–31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5–35.7) (
p
= 0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1–16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7–20.1) (
p
= 0.65).
Conclusion
Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30868388</pmid><doi>10.1007/s12094-019-02080-4</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1653-6155</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2019-11, Vol.21 (11), p.1518-1523 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2191358285 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease Susceptibility Exanthema - chemically induced Female Hand-Foot Syndrome - etiology Humans Hypertension - chemically induced Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Mucous Membrane Oncology Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Progression-Free Survival Pyridines - administration & dosage Pyridines - adverse effects Research Article Retrospective Studies Sarcopenia - chemically induced Sarcopenia - diagnostic imaging Sarcopenia - mortality Tomography, X-Ray Computed |
| title | Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T02%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relation%20between%20sarcopenia%20and%20dose-limiting%20toxicity%20in%20patients%20with%20metastatic%20colorectal%20cancer%20who%20received%20regorafenib&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=G%C3%B6kyer,%20A.&rft.date=2019-11-01&rft.volume=21&rft.issue=11&rft.spage=1518&rft.epage=1523&rft.pages=1518-1523&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-019-02080-4&rft_dat=%3Cproquest_cross%3E2191358285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2191358285&rft_id=info:pmid/30868388&rfr_iscdi=true |